BioCentury | Feb 15, 2020
Translation in Brief

COVID-19 therapy from Emory and diagnostic from Sherlock co-founders; plus Genentech, Homology and more

Emory, UNC to test nucleoside analog against COVID-19  The Emory Institute for Drug Development and University of North Carolina at Chapel Hill are conducting preclinical studies of nucleoside analog to treat COVID-19, an Emory University...
BioCentury | Feb 4, 2020
Product Development

Feb. 3 Product Development Quick Takes: European Commission’s €10M coronavirus program; plus Seqirus, Seattle Genetics, Merck, Lilly, NIAID

EC outlines €10M coronavirus program  The European Commission said it will use €10 million from its Horizon 2020 program to fund research into prevention and treatment of 2019-nCoV acute respiratory disease. The funding is expected...
BioCentury | Jan 29, 2020
Distillery Therapeutics

WWTR1-AXL-ABL2 axis inhibition for brain metastases in lung cancer

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Blocking a signaling loop comprised of the transcription factor WWTR1 and the tyrosine kinases AXL and ABL2 could treat metastatic lung cancer. AXL and ABL2 signal between each other,...
BC Extra | Jan 9, 2020
Company News

Blueprint gets first FDA approval, with second expected this year

FDA approved Blueprint’s gastrointestinal stromal tumor therapy a month ahead of its Feb. 14 PDUFA date, notching the biotech the first of two expected approvals this year. Ayvakit avapritinib from Blueprint Medicines Corp. (NASDAQ:BPMC) is...
BioCentury | Jan 9, 2020
Targets & Mechanisms

Cancer's trajectory, as viewed by targets at AACR, ASCO and ASH

Beyond the headliner presentations at 2019’s three major cancer conferences were over a hundred posters and presentations showcasing new or emerging targets. A look at the identity of those targets reveals the growing diversity of...
BC Extra | Jan 8, 2020
Company News

Pralsetinib data puts Blueprint on track for two FDA decisions this year

Blueprint moved a step closer to having two precision cancer therapies approved this year after announcing it started a rolling submission of an NDA for RET inhibitor pralsetinib along with updated Phase I/II data. Blueprint...
BioCentury | Jan 1, 2020
Regulation

Fewer FDA approvals in 2019, but a basket of firsts

While the year held fewer approvals of new molecular entities than 2018, it was not short of major achievements. FDA greenlit several drugs with innovative modalities, against novel targets and for diseases that have long...
BC Extra | Dec 19, 2019
Company News

PharmaMar deal adds late-stage asset to Jazz’s growing cancer pipeline

Jazz’s deal to gain exclusive, U.S. rights to PharmaMar’s Zepsyre marks the company’s third cancer partnership of the year, adding a late-stage asset in small cell lung cancer as it continues to expand its pipeline...
BC Extra | Dec 17, 2019
Financial News

Cellestia plans Phase II for solid, blood cancers with $20M series B

Cellestia is developing what could be a first-in-class small molecule that prevents assembly of transcription factor complexes that activate oncogene expression, and has raised CHF20 million ($20.3 million) in a B round that’ll enable completion...
BC Extra | Dec 5, 2019
Company News

Loxo to become face of new Lilly cancer unit

Eleven years after transforming its cancer operations through the purchase of ImClone, Lilly is following a similar blueprint by making its Loxo acquisition the centerpiece of its oncology R&D strategy. The $6.5 billion acquisition of...
Items per page:
1 - 10 of 2365
BioCentury | Feb 15, 2020
Translation in Brief

COVID-19 therapy from Emory and diagnostic from Sherlock co-founders; plus Genentech, Homology and more

Emory, UNC to test nucleoside analog against COVID-19  The Emory Institute for Drug Development and University of North Carolina at Chapel Hill are conducting preclinical studies of nucleoside analog to treat COVID-19, an Emory University...
BioCentury | Feb 4, 2020
Product Development

Feb. 3 Product Development Quick Takes: European Commission’s €10M coronavirus program; plus Seqirus, Seattle Genetics, Merck, Lilly, NIAID

EC outlines €10M coronavirus program  The European Commission said it will use €10 million from its Horizon 2020 program to fund research into prevention and treatment of 2019-nCoV acute respiratory disease. The funding is expected...
BioCentury | Jan 29, 2020
Distillery Therapeutics

WWTR1-AXL-ABL2 axis inhibition for brain metastases in lung cancer

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Blocking a signaling loop comprised of the transcription factor WWTR1 and the tyrosine kinases AXL and ABL2 could treat metastatic lung cancer. AXL and ABL2 signal between each other,...
BC Extra | Jan 9, 2020
Company News

Blueprint gets first FDA approval, with second expected this year

FDA approved Blueprint’s gastrointestinal stromal tumor therapy a month ahead of its Feb. 14 PDUFA date, notching the biotech the first of two expected approvals this year. Ayvakit avapritinib from Blueprint Medicines Corp. (NASDAQ:BPMC) is...
BioCentury | Jan 9, 2020
Targets & Mechanisms

Cancer's trajectory, as viewed by targets at AACR, ASCO and ASH

Beyond the headliner presentations at 2019’s three major cancer conferences were over a hundred posters and presentations showcasing new or emerging targets. A look at the identity of those targets reveals the growing diversity of...
BC Extra | Jan 8, 2020
Company News

Pralsetinib data puts Blueprint on track for two FDA decisions this year

Blueprint moved a step closer to having two precision cancer therapies approved this year after announcing it started a rolling submission of an NDA for RET inhibitor pralsetinib along with updated Phase I/II data. Blueprint...
BioCentury | Jan 1, 2020
Regulation

Fewer FDA approvals in 2019, but a basket of firsts

While the year held fewer approvals of new molecular entities than 2018, it was not short of major achievements. FDA greenlit several drugs with innovative modalities, against novel targets and for diseases that have long...
BC Extra | Dec 19, 2019
Company News

PharmaMar deal adds late-stage asset to Jazz’s growing cancer pipeline

Jazz’s deal to gain exclusive, U.S. rights to PharmaMar’s Zepsyre marks the company’s third cancer partnership of the year, adding a late-stage asset in small cell lung cancer as it continues to expand its pipeline...
BC Extra | Dec 17, 2019
Financial News

Cellestia plans Phase II for solid, blood cancers with $20M series B

Cellestia is developing what could be a first-in-class small molecule that prevents assembly of transcription factor complexes that activate oncogene expression, and has raised CHF20 million ($20.3 million) in a B round that’ll enable completion...
BC Extra | Dec 5, 2019
Company News

Loxo to become face of new Lilly cancer unit

Eleven years after transforming its cancer operations through the purchase of ImClone, Lilly is following a similar blueprint by making its Loxo acquisition the centerpiece of its oncology R&D strategy. The $6.5 billion acquisition of...
Items per page:
1 - 10 of 2365